Clinical Trial Update: Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects [NA]

View source ↗

Summary

A completed clinical trial update reporting analysis of the XTR006 PET imaging agent across non-cognitively impaired individuals, mild cognitive impairment due …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• XTR006 (XTR006)

Snippet

Sponsor: Sinotau Pharmaceutical Group | Conditions: Alzheimer Disease | NA | Status: COMPLETED